Skip to main content

Research Repository

Advanced Search

Outputs (81)

Real-world use of fumaric acid esters in psoriasis: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2017)
Presentation / Conference
Mason, K. J., Lunt, M., Hunter, H. J., Jabbar-Lopez, Z. K., Kirby, B., Kleyn, C. E., …Grp, B. A. D. B. I. R. S. (2017, November). Real-world use of fumaric acid esters in psoriasis: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Paper presented at Psoriasis Gene to Clinic, 8th International Congress, The Queen Elizabeth II Conference Centre, London, UK

Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength (2017)
Journal Article
Thorneloe, R. J., Griffiths, C. E., Emsley, R., Ashcroft, D. M., Cordingley, L., Biologic Interventions Register, B. A. O. D., …Warren, R. (2018). Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength. Journal of Investigative Dermatology, 138(4), 785 - 794. https://doi.org/10.1016/j.jid.2017.11.015

Medication non-adherence is a missed opportunity for therapeutic benefit. We assessed "real-world" levels of self-reported non-adherence to conventional and biologic systemic therapies used for psoriasis and evaluated psychological and biomedical fac... Read More about Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength.

Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). (2017)
Journal Article
Iskandar, I. Y., Warren, R. B., Lunt, M., Mason, K. J., Evans, I., McElhone, K., …Griffiths, C. E. (2018). Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 138(4), 775 - 784. https://doi.org/10.1016/j.jid.2017.09.044

Little is known about the drug survival of second-line biologic therapies for psoriasis in routine clinical practice. We assessed drug survival of second-line biologic therapies and estimated the risk of recurrent discontinuation due to adverse event... Read More about Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)..

Completeness of reporting of overnight hospitalisations to a psoriasis pharmacovigilance register and the National Health Service Wales Informatics Service (2017)
Presentation / Conference
Mason, K. J., Ali, H., Reynolds, N. J., Burden, A. D., Smith, C. H., Evans, I., …Griffiths, C. E. . M. (2017, August). Completeness of reporting of overnight hospitalisations to a psoriasis pharmacovigilance register and the National Health Service Wales Informatics Service. Paper presented at 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Palais de Congres de Montreal, Montreal, Canada

Background: The British Association of Dermatologists Biologic Interventions Register (BADBIR) is a longitudinal, observational, web-based pharmacovigilance register of patients with moderate-to-severe psoriasis. Patients are currently recruited from... Read More about Completeness of reporting of overnight hospitalisations to a psoriasis pharmacovigilance register and the National Health Service Wales Informatics Service.

Persistence with second-line biological therapies in patients with psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2017)
Presentation / Conference
Iskandar, I. Y. K., Warren, R., Lunt, M., Mason, K. J., Evans, I., McElhone, K., …Ashcroft, D. M. (2017, July). Persistence with second-line biological therapies in patients with psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Paper presented at The 97th Annual meeting of the British Association of Dermatologists, The Arena and Convention Centre Liverpool, Liverpool, United Kingdom

Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study (2017)
Journal Article
Davison, N. J., Warren, R. B., Mason, K. J., McElhone, K., Kirby, B., Burden, A. D., …Griffiths, C. E. M. (2017). Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study. British Journal of Dermatology, 177(3), 828-836. https://doi.org/10.1111/bjd.15551

Completeness of Reporting of Basal Cell Carcinoma and Squamous Cell Carcinoma to a Pharmacovigilance Register and the Health and Social Care Information Centre (2016)
Presentation / Conference
Mason, K. J., Lunt, M., Reynolds, N. J., Ashcroft, D. M., Burden, A. . D., Ormerod, A. D., …Griffiths, C. E. . M. (2016, August). Completeness of Reporting of Basal Cell Carcinoma and Squamous Cell Carcinoma to a Pharmacovigilance Register and the Health and Social Care Information Centre. Paper presented at The Convention Centre Dublin, Dublin, Ireland

32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management

The impact of musculoskeletal conditions on outcomes of other illnesses (the MSKCOM study): a linked electronic health record study - Code lists
Dataset
Marshall, M., Mason, K., Bailey, J., Heron, N., Achanca, F., Chen, Y., …Jordan, K. (2022). The impact of musculoskeletal conditions on outcomes of other illnesses (the MSKCOM study): a linked electronic health record study - Code lists. [Dataset]

Marshall M, Mason K, Bailey J, Heron N, Achana F, Chen Y, Edwards J, Frisher M, Huntley A, Mallen C, Mamas M, Png ME, Tatton S, White S, Jordan KP. MSKCOM: main Public Output: The impact of musculoskeletal conditions on outcomes of other illnesses: a... Read More about The impact of musculoskeletal conditions on outcomes of other illnesses (the MSKCOM study): a linked electronic health record study - Code lists.